Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?
by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Non-steroidal mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs) are emerging therapeutic approaches in primary aldosteronism (PA). Evidence from randomized trials, single-arm studies, real-world analyses, and ongoing clinical programs evaluates the efficacy, biochemical outcomes, and safety of finerenone, baxdrostat, and dexfadrostat. Key Evidence – MRAs: […]